GSK Promotes Ease Of Switching HIV Patients To Monthly Injection, Even During A Pandemic
Aiming To Seize Market Share From Gilead
Doctors and patients need to be persuaded of the benefits of switching from familiar oral therapies to Cabenuva, the once-monthly anti-HIV injection.
You may also be interested in...
ViiV Healthcare’s head of R&D tells Scrip that extending the durations of its long acting HIV treatments is possible using drug delivery technology from Halozyme Therapeutics to expand the body’s capacity to absorb injected medicines.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.